A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences ...

As a quirky feature of the U.S. market, not having a therapeutic interchangeability designation is considered an important impediment to physician and patient confidence in biosimilars.

Number 4: The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to ...